



January 12, 2021

TMRC Co., Ltd

TMRC Signed a Biomarker License Agreement with Syros Pharmaceuticals

On January 12, 2021, TMRC Co., Ltd. (“TMRC” Naoki Tani, President & CEO, Tokyo, Japan) entered into a Biomarker license agreement with Syros Pharmaceuticals Inc. (“Syros” Nancy Simonian, CEO, Massachusetts, USA) for a retinoic acid receptor α agonist (tamibarotene/TM-411/SY1425, hereinafter “tamibarotene”) for certain Asian territories. Tamibarotene is a drug that TMRC has licensed to Syros.

In September 2015, TMRC signed a license agreement (hereinafter “Tamibarotene License Agreement”) to grant Syros the development and marketing rights of tamibarotene as an anti-cancer agent in North America and Europe. Under the agreement, Syros is currently developing tamibarotene as a cancer drug using a biomarker developed by Syros. In this Agreement, TMRC is entitled to receive upfront and milestone payments according to the development stage of tamibarotene as well as post-launch royalties.

Given the steady development of tamibarotene by Syros, Syros has agreed to grant TMRC an exclusive right to license Syros’ RARA positive/negative biomarker patent and its know-how for the Asian territory, including Japan and China. The agreement will enable TMRC to use the biomarker patent and the know-how to pre-select RARA-positive patients who may get therapeutic benefit from tamibarotene.

Furthermore, TMRC will be able to conduct licensing activities for tamibarotene under the biomarker patent and its know-how in the Asian territory with the development protocol similar to that of the clinical trials developed by Syros in the U.S.A.

TMRC and Syros will further strengthen their collaboration via these agreements to maximize the value of tamibarotene for RARA biomarker selected patient populations. Both companies will continue to strive to deliver innovative drugs to patients around the world.

